Market News AIOpen the app

Lantern Pharma Inc. has been told it might be removed from Nasdaq for not meeting listing rules.

TroubleRead the original at SEC EDGAR
Bad for LTRN

Lantern Pharma’s listed securities stayed below Nasdaq’s $35 million minimum for 30 consecutive business days, and it also fails 2 other listing tests. The company has 180 days to qualify again, but possible removal from Nasdaq makes this negative for Lantern Pharma.

LTRN · Lantern Pharma Inc.

AI read · Bad for LTRN

The AI's read

The deadline gives Lantern Pharma a chance to fix the listing problem. Failing to do so could remove its shares from Nasdaq, making them harder to trade and weakening the company’s access to investors. That chance to fix the problem helps, but the risk of removal makes this negative for Lantern Pharma.

Get alerts for LTRN

Follow Lantern Pharma Inc. (LTRN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LTRN
Free on the App Store and Google Play, or on the web.